加载中
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
前收盘价
US$26.40
−US$0.10 · -0.38%
盘后
US$26.78
+US$0.38 · +1.44%
10月9日 19:46 ET
盘中时间采用ET。市场数据可能有所延迟。
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
日内区间
当前US$26.40
52周区间
当前US$26.40
盘中时间采用ET。市场数据可能有所延迟。
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
日内区间
当前US$26.40
52周区间
当前US$26.40
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 92.5万 USD | — | — | — |
| 销货成本 | 319.2万 USD | 324.7万 USD | 326.2万 USD | 319.6万 USD | 4226.4万 USD |
| 毛利 | −319.2万 USD | −232.2万 USD | −326.2万 USD | −319.6万 USD | −4226.4万 USD |
| 研究与开发 | 7501.1万 USD | 6091.7万 USD | 4439.4万 USD | 4750.5万 USD | 4226.4万 USD |
| 销售、一般及管理费用 | 2512.5万 USD | 2261.3万 USD | 1118.9万 USD | 901.2万 USD | 827万 USD |
| 营业费用 | 1亿 USD | 8028.3万 USD | 5232.1万 USD | 5332.1万 USD | 827万 USD |
| 利息收入 | 1154.7万 USD | 846.7万 USD | 295.1万 USD | 133.7万 USD | 1.9万 USD |
| 利息支出 | 5000 USD | 1.2万 USD | 1.2万 USD | 2000 USD | — |
| 折旧和摊销 | 309.2万 USD | 324.7万 USD | 329.7万 USD | 320万 USD | 94.7万 USD |
| 营业利润 | −1.03亿 USD | −8260.5万 USD | −5558.3万 USD | −5651.7万 USD | −5053.4万 USD |
| 净利润 | −9035.1万 USD | −7514.4万 USD | −3631.7万 USD | −5518.9万 USD | −5051.7万 USD |
公司数据更新于 2026年10月10日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$72.00
上涨空间 172.73%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年12月19日 | 1:4 | — | — |
股票拆分 | 2023年9月25日 | 1:5 | — | — |
已生效 2023年12月19日
1:4
已生效 2023年9月25日
1:5
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM1087.63万0.01%782.66亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI734.18万0.07%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 Value ETFIWN384.9万0.03%138.48亿 USD0.24%US$210.87-0.04%
iShares Biotechnology ETFIBB327.4万0.03%102.79亿 USD0.44%US$206.49+3.00%
Fidelity Enhanced Small Cap ETFFESM289.97万0.04%64.1亿 USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO235.71万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC131.73万0.10%13.17亿 USD0.60%US$183+0.11%
Vanguard Health Care ETFVHT114.28万0.01%220亿 USD0.09%US$319.01+1.64%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
